Chemotherapy for low-grade bladder cancer that comes back
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether putting two chemotherapy drugs (gemcitabine and docetaxel) directly into the bladder can treat low-grade bladder cancer that is at intermediate risk. The goal is to see if this approach can help people avoid more invasive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have low-grade bladder cancer that has come back, is larger than 3 cm, or is in more than one spot.
- Your cancer hasn't spread to the kidneys or ureters (tubes from kidneys to bladder).
- You haven't had BCG treatment before for bladder cancer.
- You have enough healthy blood cells (neutrophils and platelets) to safely receive chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
This trial tests a new, precise way to use chemotherapy to remove low-risk, non-muscle-invasive bladder tumors before surgery. It may be an option for people with small, slow-growing tumors that haven't spread into the bladder muscle.
This trial tests if the drug dutasteride can help people with a slow-growing type of bladder cancer that hasn't spread into the muscle wall. It may be an option for those not receiving other standard treatments like BCG therapy or chemotherapy directly into the bladder.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
This trial tests if you can receive chemotherapy for bladder cancer at home instead of in the clinic. It is for people with early-stage bladder cancer who are already getting certain types of intravesical (inside the bladder) treatment.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.